Moxidectin

CHEMBL2104415 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
639.8 g/mol
LogP
4.3
Phase
4

An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.

आणविक भार

639.8000 g/mol

LogP

4.30

TPSA

116.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

क्रिया का तंत्र

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C

InChI

InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1

Molecular Formula

C37H53NO8

HBD / HBA

2 / 9

घूर्णनीय बंधन

3

भारी परमाणु

46

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

An antiparasitic agent used to treat onchocerciasis (river blindness) and is also used in veterinary medicine against a wide range of internal and external parasites. It works by activating glutamate-gated chloride channels in parasites, causing paralysis and death.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Moxidectin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2104415. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9832912. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.